Renovacor, Inc., (RCOR) News
Filter RCOR News Items
RCOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RCOR News From Around the Web
Below are the latest news stories about RENOVACOR INC that investors may wish to consider to help them evaluate RCOR as an investment opportunity.
Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy CongressCAMBRIDGE, Mass., October 10, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company’s chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentat |
Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies ConferenceCAMBRIDGE, Mass., September 26, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation |
Renovacor (NYSE: RCOR) Up After Acquisition By Rocket PharmaShares of Renovacor (NYSE: RCOR) were up in early morning trading on Tuesday following the news of its acquisition by Rocket Pharmaceuticals (RCKT). Rocket will acquire Renovacor in an all-stock deal for $2.60 per share, based on the volume-weighted average trading price of Rocket stock priced at $15.51 for the 30 trading days through and including Monday, September 19. Renovacor is a biotechnology company focused on delivering innovative precision therapies for genetic cardiovascular diseases. As a part of this deal, Renovacor shareholders will receive around 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and upon the close of the transaction, will own approximately 4. |
Fed Rate Hikes 2022: Investors, Mark Your Calendars for Sept. 21The Federal Reserve is planning to reveal additional interest rate hikes tomorrow that investors will want to know about! |
Rumble (RUM) Stock Plunges on Second Trading DayRumble (RUM) stock is on the move Tuesday as the YouTube alternative is seeing volatility during its second day of trading. |
Why Is Renovacor (RCOR) Stock Up 18% Today?Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal. |
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene TherapyCRANBURY, N.J. & CAMBRIDGE, Mass., September 20, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-relate |
Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateCAMBRIDGE, Mass., August 08, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the second quarter of 2022 and provided a corporate update. |
Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic CardiomyopathyCAMBRIDGE, Mass., July 12, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has ent |
Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational ResearchCAMBRIDGE, Mass., June 01, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion (RCSI) in healthy Yucatan pigs. The paper, titled, "C |